Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1527.00    12.00 (0.79%)
Bid:
1532.00
Ask:
1534.00
Spread: 2.00 (0.131%)
Market Cap: £3.21b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

31 May 2023 15:20

RNS Number : 2161B
Hikma Pharmaceuticals Plc
31 May 2023
Β 

Β 

Hikma Pharmaceuticals PLC - LTIP and EIP Awards

Β 

LONDON, 31 May 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP"); the 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 30 May 2023 based on a price of Β£18.43 per Ordinary Share (being the average mid-market Ordinary Share price for the for the 5-working day period prior to 30 May 2023, in accordance with the LTIP rules) (the "LTIP Awards"). The vesting of the LTIP Awards is subject to the continued employment of the PDMRs, malus and clawback provisions and the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP Awards are then subject to an additional two-year holding period.

Awards under the EIP were made on 30 May 2023 based on a price of Β£15.15 per Ordinary Share (being the average mid-market Ordinary Share price for the 30-day period prior to 31 December 2022, in accordance with the EIP rules) (the "EIP Awards"). All EIP Awards are subject to malus and clawback provisions. EIP Element B Awards will normally vest on the second anniversary of the date of grant, subject to continued employment, and are then subject to an additional three-year holding period. EIP Element C Awards will normally vest on the third anniversary of the date of grant, subject to continued employment, and are then subject to an additional two-year holding period.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 132,783 Shares

Nil

EIP Award, Element B: 31,679 Shares

Nil

EIP Award, Element C: 19,761 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 184,223

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 105,233 Shares

Nil

EIP Award, Element B: 36,171 Shares

Nil

EIP Award, Element C: 20,650 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 162,054

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 76,130 Shares

Nil

EIP Award, Element B: 28,647 Shares

Nil

EIP Award, Element C: 20,982 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,759

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 74,699 Shares

Nil

EIP Award, Element B: 28,833 Shares

Nil

EIP Award, Element C: 22,209 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,741

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 75,339 Shares

Nil

EIP Award, Element B: 36,371 Shares

Nil

EIP Award, Element C: 30,749 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 142,459

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 50,301 Shares

Nil

EIP Award, Element B: 18,836 Shares

Nil

EIP Award, Element C: 13,796 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 82,933

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 38,409 Shares

Nil

EIP Award, Element B: 15,925 Shares

Nil

EIP Award, Element C: 11,664 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 65,998

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 54,422 Shares

Nil

EIP Award, Element B: 12,233 Shares

Nil

EIP Award, Element C: 8,302 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 74,957

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Hussein Arkhagha

Β 1

Β Details of the person discharging managerial responsibilities / person closely associated

Β a)

Β Name

Β Hussein Arkhagha

Β 2

Β Reason for the notification

Β a)

Β Position/status

Β PDMR

Β b)

Initial notification /Amendment

Β Initial notification

Β 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β a)

Β Name

Β Hikma Pharmaceuticals PLC

Β b)

Β LEI

Β 549300BNS685UXH4JI75

Β 4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β a)

Description of the financial instrument, type of instrument and identification code

Β Description: Ordinary shares of 10 pence each (Shares)

Β ID Code: GB00B0LCW083

Β b)

Nature of the transaction

Β 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 41,408 Shares

Nil

EIP Award, Element B: 15,983 Shares

Nil

EIP Award, Element C: 12,406 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 69,797

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Β 

Β 

Helen Middlemist

Deputy Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHBSGDUCBXDGXB
Date   Source Headline
22nd Jun 20261:11 pmRNSTransaction in Own Shares
15th Jun 202612:20 pmRNSHolding(s) in Company
15th Jun 20269:40 amRNSTransaction in Own Shares
12th Jun 20269:00 amRNSHolding(s) in Company
8th Jun 202610:00 amRNSTransaction in Own Shares
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.